Ground Swell Capital’s TransCode Therapeutics RNAZ Stock Holding History

Ground Swell Capital’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-513	Closed	-$7.11K	–	244
2025 Q1	$7.11K	Buy	+513	New	+$65.7K	0.02%	146

Other funds holding RNAZ

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SouthState Corp Winter Haven, Florida $2.14B AUM 18.39% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ground Swell Capital's RNAZ Position: Q2 2025 in Review

Ground Swell Capital sold out of TransCode Therapeutics (RNAZ) in Q2 2025, closing a stake of 513 shares — an estimated $7.11K sold.

Ground Swell Capital first reported a position in RNAZ in Q1 2025 and held it in 1 quarter. The position peaked at $7.11K in Q1 2025. 9 funds tracked by Wall St. Rank hold RNAZ as of Q2 2025.

Ground Swell Capital reported no remaining TransCode Therapeutics position as of Q2 2025 after selling out during the quarter.
Ground Swell Capital sold 513 TransCode Therapeutics shares in Q2 2025, an estimated $7.11K.
Ground Swell Capital first reported a position in TransCode Therapeutics in Q1 2025 and held it in 1 quarter.
Ground Swell Capital's TransCode Therapeutics position peaked at $7.11K in Q1 2025.
9 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q2 2025.

Based on Ground Swell Capital's 13F filing for Q2 2025, filed 31 Jul 2025.